|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
Ropivacaine results in increased expression of AIFM1 protein |
CTD |
PMID:28079261 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
Ropivacaine results in increased expression of BAX mRNA; Ropivacaine results in increased expression of BAX protein pifithrin inhibits the reaction [Ropivacaine results in increased expression of BAX mRNA]; pifithrin inhibits the reaction [Ropivacaine results in increased expression of BAX protein] |
CTD |
PMID:34091999 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases response to substance decreases expression multiple interactions |
ISO EXP |
BCL2 protein results in decreased susceptibility to Ropivacaine Ropivacaine results in decreased expression of BCL2 mRNA; Ropivacaine results in decreased expression of BCL2 protein pifithrin inhibits the reaction [Ropivacaine results in decreased expression of BCL2 mRNA]; pifithrin inhibits the reaction [Ropivacaine results in decreased expression of BCL2 protein] BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of CASP3 protein]; BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein] |
CTD |
PMID:15538973 PMID:34091999 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression decreases expression |
ISO EXP |
Ropivacaine results in increased cleavage of CASP3 protein pifithrin inhibits the reaction [Ropivacaine results in increased cleavage of CASP3 protein]; pifithrin inhibits the reaction [Ropivacaine results in increased expression of CASP3 mRNA] BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of CASP3 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased expression of CASP3 protein] Ropivacaine results in decreased expression of CASP3 protein |
CTD |
PMID:15538973 PMID:20194319 PMID:34091999 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
Ropivacaine results in decreased expression of CASP9 protein |
CTD |
PMID:20194319 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Clu |
clusterin |
multiple interactions decreases expression decreases response to substance |
ISO |
CLU protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased expression of CASP3 protein] Ropivacaine results in decreased expression of CLU protein CLU protein results in decreased susceptibility to Ropivacaine |
CTD |
PMID:15538973 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Hrh1 |
histamine receptor H 1 |
affects binding |
ISO |
HRH1 protein binds to Ropivacaine |
CTD |
PMID:32061592 |
|
NCBI chr 4:147,564,781...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] |
CTD |
PMID:9336308 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] |
CTD |
PMID:9336308 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
multiple interactions |
ISO |
Ropivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16931984 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
decreases activity multiple interactions |
ISO |
Ropivacaine results in decreased activity of KCNQ1 protein Ropivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16931984 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage increases expression multiple interactions |
ISO |
Ropivacaine results in increased cleavage of PARP1 protein Ropivacaine results in increased expression of PARP1 protein BCL2 protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein]; CLU protein inhibits the reaction [Ropivacaine results in increased cleavage of PARP1 protein] |
CTD |
PMID:15538973 PMID:28079261 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sell |
selectin L |
multiple interactions |
ISO |
Ropivacaine inhibits the reaction [TNF protein results in increased cleavage of SELL protein] |
CTD |
PMID:9336308 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO |
SULT1A1 protein results in increased sulfation of Ropivacaine metabolite |
CTD |
PMID:10460806 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
increases sulfation |
ISO |
SULT1E1 protein results in increased sulfation of Ropivacaine metabolite |
CTD |
PMID:10460806 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Ropivacaine inhibits the reaction [TNF protein results in increased cleavage of SELL protein]; Ropivacaine inhibits the reaction [TNF protein results in increased expression of [ITGAM protein binds to ITGB2 protein]] |
CTD |
PMID:9336308 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
EXP |
pifithrin inhibits the reaction [Ropivacaine results in increased expression of TP53 mRNA]; pifithrin inhibits the reaction [Ropivacaine results in increased expression of TP53 protein] Ropivacaine results in increased expression of TP53 mRNA; Ropivacaine results in increased expression of TP53 protein |
CTD |
PMID:34091999 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Bupivacaine results in increased expression of BAX protein 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of BAX protein]; [Glucose co-treated with Bupivacaine] results in increased expression of BAX protein |
CTD |
PMID:31672611 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Bupivacaine results in decreased expression of BCL2 protein 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one promotes the reaction [[Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein]; [Glucose co-treated with Bupivacaine] results in decreased expression of BCL2 protein |
CTD |
PMID:31672611 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Casp3 |
caspase 3 |
decreases expression increases activity |
ISO EXP |
Bupivacaine results in decreased expression of CASP3 protein Bupivacaine results in increased activity of CASP3 protein |
CTD |
PMID:16109997 PMID:20194319 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
Bupivacaine results in decreased expression of CASP9 protein |
CTD |
PMID:20194319 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
EXP |
[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of CYP3A9 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Entpd4 |
ectonucleoside triphosphate diphosphohydrolase 4 |
multiple interactions |
EXP |
[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of ENTPD4 mRNA |
CTD |
PMID:22341215 |
|
NCBI chr15:44,630,873...44,658,706
Ensembl chr15:44,630,873...44,658,706
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
Glucose promotes the reaction [Bupivacaine results in increased expression of H2AX protein] |
CTD |
PMID:31672611 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hpgds |
hematopoietic prostaglandin D synthase |
increases expression |
ISO |
Bupivacaine results in increased expression of HPGDS mRNA; Bupivacaine results in increased expression of HPGDS protein |
CTD |
PMID:19359520 |
|
NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
|
|
G |
Hrh1 |
histamine receptor H 1 |
affects binding |
ISO |
HRH1 protein binds to Bupivacaine |
CTD |
PMID:32061592 |
|
NCBI chr 4:147,564,781...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Itgam |
integrin subunit alpha M |
increases expression multiple interactions |
ISO |
Bupivacaine results in increased expression of ITGAM mRNA 4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine inhibits the reaction [Bupivacaine results in increased expression of ITGAM mRNA] |
CTD |
PMID:19359520 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
multiple interactions |
ISO |
Bupivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]; KCNE1 protein inhibits the reaction [KCNQ1 protein mutant form results in increased susceptibility to Bupivacaine] |
CTD |
PMID:16931984 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnk9 |
potassium two pore domain channel subfamily K member 9 |
multiple interactions |
ISO |
Bupivacaine inhibits the reaction [KCNK9 protein results in increased transport of Potassium] |
CTD |
PMID:11249964 |
|
NCBI chr 7:104,429,186...104,473,924
Ensembl chr 7:104,437,934...104,473,175
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
multiple interactions decreases activity increases response to substance |
ISO |
Bupivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein]; KCNE1 protein inhibits the reaction [KCNQ1 protein mutant form results in increased susceptibility to Bupivacaine] Bupivacaine results in decreased activity of KCNQ1 protein |
CTD |
PMID:16931984 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Bupivacaine results in increased phosphorylation of MAPK1 protein Glucose promotes the reaction [Bupivacaine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34060177 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Bupivacaine results in increased phosphorylation of MAPK3 protein Glucose promotes the reaction [Bupivacaine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34060177 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myf5 |
myogenic factor 5 |
decreases expression |
EXP |
Bupivacaine results in decreased expression of MYF5 protein |
CTD |
PMID:10434046 |
|
NCBI chr 7:42,802,946...42,806,177
Ensembl chr 7:42,802,946...42,806,177
|
|
G |
Myod1 |
myogenic differentiation 1 |
decreases expression |
EXP |
Bupivacaine results in decreased expression of MYOD1 protein |
CTD |
PMID:10434046 |
|
NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Myog |
myogenin |
decreases expression |
EXP |
Bupivacaine results in decreased expression of MYOG protein |
CTD |
PMID:10434046 |
|
NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
EXP |
[Bupivacaine co-treated with Tetrodotoxin co-treated with Dexamethasone] results in decreased expression of PRKCB mRNA |
CTD |
PMID:22341215 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
affects expression |
ISO |
Bupivacaine affects the expression of PTGDR mRNA |
CTD |
PMID:19359520 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases expression |
ISO |
Bupivacaine results in increased expression of PTGS1 mRNA |
CTD |
PMID:18165598 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Bupivacaine results in increased expression of PTGS2 mRNA [Bupivacaine results in increased expression of PTGS2] which results in increased abundance of Dinoprostone |
CTD |
PMID:18165598 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
Bupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine] |
CTD |
PMID:16725121 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity multiple interactions |
EXP |
Bupivacaine results in increased activity of TRPV1 protein Bupivacaine affects the reaction [Capsaicin results in increased activity of TRPV1 protein] |
CTD |
PMID:15854744 PMID:18172555 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Xrcc6 |
X-ray repair cross complementing 6 |
increases expression multiple interactions |
ISO |
Bupivacaine results in increased expression of XRCC6 protein 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one inhibits the reaction [[Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein]; [Glucose co-treated with Bupivacaine] results in increased expression of XRCC6 protein; Glucose inhibits the reaction [Bupivacaine results in increased expression of XRCC6 protein] |
CTD |
PMID:31672611 |
|
NCBI chr 7:113,542,992...113,563,762
Ensembl chr 7:113,543,057...113,563,762
|
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
multiple interactions |
ISO |
Mepivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16931984 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
decreases activity multiple interactions |
ISO |
Mepivacaine results in decreased activity of KCNQ1 protein Mepivacaine results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16931984 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity |
EXP |
Mepivacaine results in increased activity of TRPV1 protein |
CTD |
PMID:18172555 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|